Home | About PharmaCorner | Guest Book | Advertising | Site Map | Contact us
23 Jun 2017 Welcome visitor
Search
Login | Register
Pharmacy Ethics
The Calculator
Pharmacy News
Ask The Expert
FAQ´s
Training Programs
Parenteral Medications
Hazardous Medications
Continuing Education
Pharmacy History
Public Education
Important Links
Services


 
Enter your Email address

Home > Pharmacy News >Drug Alerts > A Possible Link between Cellcept, Myfortec and a Fatal Neurological Disorder

(15-04-2008) The FDA is investigating a potential link between CellCept® (mycophenolate mofetil) and Myfortic® (mycophenolic acid) and the development of progressive multifocal leukoencephalopathy (PML), a rare life-threatening neurological disorder, usually occurs in immunocompromised patients. It attacks the brain and central nervous system and is usually fatal. Symptoms include vision problems, loss of coordination and memory loss. Patients who survive are often permanently disabled, according to the FDA. Cellcept® is used to avoid rejection in organ transplant patients. The disorder was also seen in patients taking the drug for a form of lupus, a use that is not approved by regulators.

Roche Company, the drug maker, alerted the regulators about this association last November 2007. According to company spokesman, Roche has independently confirmed 10 cases of the disease in CellCept patients, He added that the drug has been used by an estimated 500,000 patients worldwide.

On the other hand, The Food and Drug Administration has identified 16 cases of patients developing this rare neurological ailment while taking Roche's drug CellCept, The agency said it will take about two months to review the reports and approve new labeling for the medications. Until then, regulators advise doctors and patients to watch for symptoms of neurological problems.

Reference:

All Rights Reserved to pharmacorner 2007 - Disclaimer - Contact us